# OnCo record majestec-3 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/majestec-3/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "majestec-3", "NCT05083169" ;
  schema:name "MajesTEC-3"@en ;
  schema:description "A bispecific plus daratumumab cut the risk of progression by more than 80% versus standard doublets, bringing bispecifics to second line."@en ;
  schema:url <https://onco.cc/trials/majestec-3/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05083169>, <https://www.jnj.com/media-center/press-releases/johnson-johnson-announces-u-s-fda-approval-of-tecvayli-plus-darzalex-faspro-for-relapsed-refractory-multiple-myeloma-offering-a-potential-new-standard-of-care-as-early-as-second-line> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2021-10-14" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:drugs <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/daratumumab/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:people <https://onco.cc/people/philippe-moreau/> .